Evidence mapPaperPMID 36650625Full record

ReviewCurrent diabetes reviews2023

Evolution of Guideline Recommendations on Insulin Therapy in Type 2 Diabetes Mellitus Over the Last Two Decades: A Narrative Review.

Manoj Chadha, Sunil M Jain, Rajeev Chawla, Mala Dharmalingam, Tirthankar Chaudhury, P G Talwalkar, Sudhir Tripathi, S K Singh, Manish Gutch, Arundhati Dasgupta

Abstract readReview
In one paragraph

Review in Current diabetes reviews, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed, 1 pooled it
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Tubeless Insulin Pump Combined with a Cloud-Based Data Management Platform: Real-World Evidence from 14,765 French People with Diabetes.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2025
    Article
  3. Article
  4. Type 2 diabetes mellitus, antidiabetics, and the risk of amyotrophic lateral sclerosis.Amyotrophic lateral sclerosis & frontotemporal degeneration · 2025
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. LIVE INDIA: Effectiveness of Gla-100 in a Post hoc Pooled Analysis of FINE ASIA and GOAL Registries.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2023
    Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Manoj ChadhaDepartment of Endocrinology, P.D. Hinduja Hospital, Mumbai, Maharashtra, India.
Sunil M JainTOTALL Diabetes Hormone Institute, Indore, Madhya Pradesh, India.
Rajeev ChawlaDepartment of Endocrinology, North Delhi Diabetes Centre, Rohini, New Delhi, India.
Mala DharmalingamDepartment of Endocrinology, MSR Medical College & Hospital, Bangalore, Karnataka, India.
Tirthankar ChaudhuryDepartment of Endocrinology, Apollo Gleneagles Hospital, Kolkata, India.
P G TalwalkarTalwalkar Diabetes Clinic, Mumbai, Maharashtra, India.
Sudhir TripathiDepartment of Endocrinology & Metabolism, Sir Gangaram Hospital, New Delhi, India.
S K SinghDepartment of Endocrinology, Institute of Medical Sciences, BHU, Varanasi, Uttar Pradesh, India.
Manish GutchDepartment of Endocrinology and Diabetes, Medanta Hospital, Lucknow, Uttar Pradesh, India.
Arundhati DasguptaDepartment of Endocrinology, Rudraksh Superspeciality Care, Siliguri, West Bengal, India.

Funding

Sanofi
6 · The paper itself

Abstract

The prevalence of type 2 diabetes mellitus has been increasing worldwide. As the therapeutic options for type 2 diabetes mellitus have evolved over the last 2 decades, national and global guidelines related to type 2 diabetes mellitus pharmacotherapy issued by various organizations have tended to vary in their recommendations. This narrative review aimed to analyze the key recommendations by major global and national guidelines on the initiation of insulin therapy in patients with type 2 diabetes mellitus over the last 20 years. Strategies for insulin therapy for titration and intensification were also assessed. All guidelines recommend initiation of insulin (basal/ premixed/other formulations) when glycemic targets are not achieved despite lifestyle measures and oral antidiabetic drugs. In the recent decade, early initiation of insulin has been recommended when the glycated hemoglobin levels are >10% or blood glucose levels are ≥300 mg/dL (16.7 mmol/L). Initiation is recommended at a dose of 10 units or 0.1-0.2 U/kg. Titration is advised to achieve the optimal dosage, while intensification is recommended when glycemic targets are not achieved despite titrating to an acceptable level. Glucose monitoring at periodic intervals is recommended for adequate glycemic control. The guidelines further suggest that the choice of insulin should be individualized, considering the clinical status of patients with type 2 diabetes mellitus. The physicians as well as patients should be a part of the decisions made regarding the therapeutic choice of regimen, preparation, and delivery device.

Indexed as

Diabetes Mellitus, Type 2InsulinBlood GlucoseBlood Glucose Self-MonitoringHumansHypoglycemic AgentsPractice Guidelines as TopicBlood GlucoseHypoglycemic AgentsInsulinGuidelineshemoglobin levelsinsulinoral antidiabeticspharmacotherapytype 2 diabetes mellitus

Identifiers

PMID36650625
PMCPMC10617785

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.